When 28-year-old Amina from East London was diagnosed with ulcerative colitis, her doctors couldn’t predict whether she’d manage her symptoms with medication or eventually face surgery. Now, thanks to a breakthrough study led by researchers in London, that uncertainty may soon be a thing of the past for thousands like her. Scientists from the Wellcome Sanger Institute, the Francis Crick Institute, and the NIHR IBD BioResource have identified a precise genetic marker—HLA-DRB1*01:03—that flags a higher risk of severe inflammatory bowel disease (IBD), offering a potential roadmap for earlier, life-changing interventions.
In the largest genetic study of IBD traits ever conducted, the team analyzed DNA from 43,762 patients across more than 100 hospitals in the UK, including 21,839 with Crohn’s disease and 21,923 with ulcerative colitis or unclassified IBD. What they found could reshape how IBD is managed: the HLA-DRB1*01:03 variant appears in about one in 20 IBD patients and is strongly linked to aggressive disease progression. Those carrying the marker were more likely to require colon surgery, suffer from perianal disease, or need advanced therapies like monoclonal antibodies—often earlier in their disease course.
For patients, this could mean the difference between years of trial-and-error treatment and a targeted approach from the start. Currently, over half a million people in the UK live with Crohn’s or ulcerative colitis—chronic, painful conditions with no cure, where symptoms range from mild discomfort to debilitating flare-ups and surgical intervention. The unpredictability of the disease has long frustrated both clinicians and patients. But this discovery opens a path toward personalized medicine, where genetic testing could guide treatment intensity from diagnosis.
"We found that IBD patients with these genetic variants within the HLA-DRB1 gene had more severe disease, including colon surgeries or advanced treatments, sometimes earlier in their disease progression," says Dr. Laura Fachal, co-senior author at the Wellcome Sanger Institute. The implications extend beyond high-risk identification—patients without the marker might safely avoid aggressive therapies, reducing unnecessary side effects and healthcare costs.
Published in The Lancet Gastroenterology & Hepatology, the study marks a significant leap in understanding the genetic architecture of IBD severity. While genetic factors have long been suspected in disease progression, this is the first time a specific HLA variant has been tied to severe outcomes across both major forms of IBD. The team now hopes to integrate this marker into clinical screening, potentially making genetic testing a routine part of IBD diagnosis.
As research moves toward real-world application, the vision is clear: a future where no patient faces the unknown. With a simple genetic test, clinicians could tailor care with precision, ensuring those who need it most get faster access to advanced treatments—turning a life of uncertainty into one of proactive management.